{"Title": "Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles", "Year": 2018, "Source": "Bioorg. Med. Chem.", "Volume": "26", "Issue": 8, "Art.No": null, "PageStart": 1797, "PageEnd": 1809, "CitedBy": 38, "DOI": "10.1016/j.bmc.2018.02.026", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85042370032&origin=inward", "Abstract": "\u00a9 2018 The AuthorsReplacing the naphthalene C-unit of the anti-tuberculosis drug bedaquiline with a range of bicyclic heterocycles of widely differing lipophilicity gave analogs with a 4.5-fold range in clogP values. The biological results for these compounds indicate on average a lower clogP limit of about 5.0 in this series for retention of potent inhibitory activity (MIC90s) against M.tb in culture. Some of the compounds also showed a significant reduction in inhibition of hERG channel potassium current compared with bedaquiline, but there was no common structural feature that distinguished these.", "AuthorKeywords": ["Bedaquiline", "Bedaquiline analogs", "Drug development", "Tuberculosis"], "IndexKeywords": ["Antitubercular Agents", "Bridged Bicyclo Compounds, Heterocyclic", "Cell Line, Tumor", "Diarylquinolines", "Dose-Response Relationship, Drug", "Humans", "Microbial Sensitivity Tests", "Molecular Structure", "Mycobacterium tuberculosis", "Naphthalenes", "Structure-Activity Relationship"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85042370032", "SubjectAreas": [["Biochemistry", "BIOC", "1303"], ["Molecular Medicine", "BIOC", "1313"], ["Molecular Biology", "BIOC", "1312"], ["Pharmaceutical Science", "PHAR", "3003"], ["Drug Discovery", "PHAR", "3002"], ["Clinical Biochemistry", "BIOC", "1308"], ["Organic Chemistry", "CHEM", "1605"]], "AuthorData": {"57216717540": {"Name": "Sutherland H.S.", "AuthorID": "57216717540", "AffiliationID": "60078730, 60005686", "AffiliationName": "Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland"}, "57196041859": {"Name": "Tong A.S.T.", "AuthorID": "57196041859", "AffiliationID": "60078730, 60005686", "AffiliationName": "Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland"}, "57196041134": {"Name": "Choi P.J.", "AuthorID": "57196041134", "AffiliationID": "60078730, 60005686", "AffiliationName": "Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland"}, "26429101700": {"Name": "Conole D.", "AuthorID": "26429101700", "AffiliationID": "60078730, 60005686", "AffiliationName": "Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland"}, "56704847700": {"Name": "Blaser A.", "AuthorID": "56704847700", "AffiliationID": "60078730, 60005686", "AffiliationName": "Auckland Cancer Society Research Centre, School of Medical Sciences, University of Auckland"}, "7102923387": {"Name": "Denny W.A.", "AuthorID": "7102923387", "AffiliationID": "60005686", "AffiliationName": "Maurice Wilkins Centre, University of Auckland"}, "7201727134": {"Name": "Palmer B.D.", "AuthorID": "7201727134", "AffiliationID": "60005686", "AffiliationName": "Maurice Wilkins Centre, University of Auckland"}, "7004722206": {"Name": "Franzblau S.G.", "AuthorID": "7004722206", "AffiliationID": "60027561", "AffiliationName": "Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago"}, "57199440607": {"Name": "Cooper C.B.", "AuthorID": "57199440607", "AffiliationID": "100374092", "AffiliationName": "Global Alliance for TB Drug Development"}, "57216717153": {"Name": "Upton A.M.", "AuthorID": "57216717153", "AffiliationID": "100374092", "AffiliationName": "Global Alliance for TB Drug Development"}, "57196222764": {"Name": "Lotlikar M.U.", "AuthorID": "57196222764", "AffiliationID": "100374092", "AffiliationName": "Global Alliance for TB Drug Development"}}}